Corcept Therapeutics Inc. is a pharmaceutical company focused on developing and commercializing drugs for severe metabolic, psychiatric, and oncologic disorders. The company specializes in researching the adverse effects of excess cortisol and developing compounds to mitigate these effects. Corcept's primary mission is to address unmet medical needs in these critical areas through innovative drug discovery and development.
The company has made significant strides in its field, contributing to advancements in the treatment of cortisol-related disorders. Corcept's work has potential implications for a wide range of patients suffering from conditions affected by cortisol imbalances. Joseph K. Belanoff, MD, serves as the CEO, president, and director, while Robert S. Fishman, MD, holds the position of chief medical officer, leading the company's clinical development efforts.
